CliffBio
small molecule

DILAUDID

HYDROMORPHONE HYDROCHLORIDE

Loss of exclusivityMarch 2034latest FDA-listed patent expiry
CompanyFresenius Kabi →View the full company profile on CliffBio

Drug detail

Brand nameDILAUDID
Active ingredientHYDROMORPHONE HYDROCHLORIDE
Strength0.5MG/0.5ML
Dosage formINJECTABLE
RouteINJECTION
ModalitySmall molecule
FDA approvalFebruary 2017
Marketing statusRX

Listed patents

PatentExpiresType
9248229March 2034product
9731082April 2032product

More from Fresenius Kabi

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Not found